Kezar Life Sciences, Inc. Quarterly Debt-to-equity in % from Q1 2019 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kezar Life Sciences, Inc. quarterly Debt-to-equity history and growth rate from Q1 2019 to Q4 2024.
  • Kezar Life Sciences, Inc. Debt-to-equity for the quarter ending December 31, 2024 was 20.5 %, a 40.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 20.5 +5.9 +40.4% Dec 31, 2024
Q3 2024 19.2 +6.21 +47.9% Sep 30, 2024
Q2 2024 17.5 +6.46 +58.8% Jun 30, 2024
Q1 2024 15.9 +6.57 +70.3% Mar 31, 2024
Q4 2023 14.6 +6.21 +73.9% Dec 31, 2023
Q3 2023 13 +4.81 +59% Sep 30, 2023
Q2 2023 11 +2.46 +28.8% Jun 30, 2023
Q1 2023 9.35 +0.24 +2.64% Mar 31, 2023
Q4 2022 8.4 -0.79 -8.59% Dec 31, 2022
Q3 2022 8.15 -0.09 -1.09% Sep 30, 2022
Q2 2022 8.53 +0.83 +10.8% Jun 30, 2022
Q1 2022 9.11 +1.75 +23.8% Mar 31, 2022
Q4 2021 9.19 +1.55 +20.3% Dec 31, 2021
Q3 2021 8.24 -0.47 -5.4% Sep 30, 2021
Q2 2021 7.7 -2.29 -22.9% Jun 30, 2021
Q1 2021 7.36 -4.46 -37.7% Mar 31, 2021
Q4 2020 7.64 -4.55 -37.3% Dec 31, 2020
Q3 2020 8.71 -1.11 -11.3% Sep 30, 2020
Q2 2020 9.99 +1.98 +24.7% Jun 30, 2020
Q1 2020 11.8 +5.24 +79.6% Mar 31, 2020
Q4 2019 12.2 Dec 31, 2019
Q3 2019 9.82 Sep 30, 2019
Q2 2019 8.01 Jun 30, 2019
Q1 2019 6.59 Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.